Coronavirus Vaccine

US government and private companies are building technologies for monitoring COVID-19 vaccine deployment, the official noted.

Human trials of Covaxin, India's first vaccine candidate against coronavirus, began at PGI Rohtak on July 17. Three volunteers were administered Covaxin on that day.

Ryan also cautioned schools to be careful about re-opening until community transmission of COVID-19 is under control. Debate in the United States over restarting education has intensified, even as the pandemic flares up in dozens of states.

It may be noted that there are 12 places where the trial for Covaxin is taking place as per the Indian Council for Medical Research (ICMR).

The Central Drug Standard Control Organisation--the office of Drug Controller General of India (DGCI)-has granted permission to initiate Phase-1 and Phase-2 clinical trial of Covaxin.

Maharashtra continues to remain the worst-affected state due to COVID-19 with 2,11,987 cases, out of which 87,699 are active, 1,15,262 have been cured/discharged and 9,026 have died.

The British drugmaker has already begun large-scale, mid-stage human trials of the vaccine, which was developed by researchers at University of Oxford.

Professor Gintsburg had earlier said that mass vaccination against the novel coronavirus may begin in Russia this fall, although the process might take up to nine months.

A total of 2104 patients randomly received 6 mg of the drug once per day (either by mouth or by intravenous injection) for ten days and were compared with 4,321 patients randomised to usual care alone.

Out of the total number of cases, 1,37,448 are active, while 1,41,029 have been cured/discharged/migrated.